![]() |
市场调查报告书
商品编码
1423558
到 2030 年经皮毒理学测试市场预测:按类型、测试方法、测试类型、最终用户和地区进行的全球分析Dermal Toxicity Testing Market Forecasts to 2030 - Global Analysis By Type (Product, Services and Other Types), Testing Method (In-vitro Testing, In-silico Modeling and In-vivo testing), Test Type, End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球经皮毒性测试市场规模为 23.2 亿美元,预计到 2030 年将达到 46 亿美元,预测期内复合年增长率为 10.3%。
经皮毒性测试是一种科学方法,用于评估化学物质与皮肤接触时的潜在有害影响。此类测试对于评估各种产品(包括化妆品、药品和工业化学品)的安全性至关重要。皮肤毒性测试评估各种参数,包括皮肤外观、红斑(发红)、水肿(肿胀)和其他刺激征兆。
根据癌症研究所统计,正在开发的活性药物数量增加了90%以上,2019年达到3,876种。目前正在考虑进行长期囓齿动物致癌性研究来评估该药物对人类的致癌性。
增加研发活动
研发活动的增加证实了开发新产品和配方对于将创新和安全的产品推向市场的重要角色。全面的经皮毒性研究对于评估这些进展的安全性至关重要。此外,满足不断变化的监管标准、保护公众健康以及向消费者灌输对新开发产品安全性的信心的需求正在推动对经皮毒性测试服务的需求。
高成本
经皮毒性测试需要专门的设施和设备才能获得准确可靠的结果。维护此类设施、取得和维护测试设备以及僱用技术人员的成本可能很高。此外,需要测试的物质的复杂性和多样性也增加了成本。此外,随着监管要求的发展,可能需要额外的测试和方法更新,导致合规成本增加,从而阻碍市场扩张。
消费者意识不断增强
人们对皮肤健康和安全的认识不断提高,促使消费者仔细检查产品标籤,并要求製造商提供透明度。消费者越来越意识到接触个人保健产品、化妆品和药品中某些化学物质所带来的潜在风险。此外,这种对安全的重视符合更广泛的消费者对健康和环境永续性优先考虑的产品趋势,这正在推动该市场的规模。
有限的标准化
缺乏标准化的通讯协定和指南给进行准确的风险评估和解释不同实验室和测试的测试结果带来了挑战。建立一致的标准来确定经皮接触物质的安全性也很困难。此外,缺乏协调导致监管机构和行业相关人员效率低下并增加成本,阻碍了市场扩张。
COVID-19 的影响
COVID-19 的爆发对经皮毒性测试市场产生了一些负面影响。经皮毒性测试市场高度依赖製药、化妆品和化学品行业,这些行业在大流行期间都受到了干扰。实验室关闭、设施准入限制和劳动力流动限制阻碍了经皮毒性测试的顺利进行,影响了产品核准和推出时间表。此外,景气衰退导致一些公司重新考虑对非必要测试服务的投资,影响了整体市场的成长。
In Silico模拟领域预计将在预测期内成为最大的领域
In Silico模拟领域预计占据最大份额,因为它旨在透过模拟分子间相互作用、吸收率以及对皮肤的潜在不利影响来准确预测经皮毒性。这些模型有助于减少动物测试,并且符合伦理考量和监管努力,以尽量减少在测试程序中使用动物。此外,机器学习和人工智慧等技术进步正在提高In Silico模型的准确性和可靠性,使其成为毒性评估的宝贵工具,并推动该领域的成长。
预计皮肤腐蚀测试产业在预测期内复合年增长率最高
预计皮肤腐蚀测试领域在预测期内复合年增长率最高。皮肤腐蚀测试是指对皮肤的严重损害,通常以皮肤组织破坏导致化学烧伤为特征。这些测试通常涉及涂布实验动物或试管内模型的皮肤,并进行观察以确定皮肤损伤的程度。此外,结果还可以帮助将物质分类为腐蚀性或非腐蚀性,为产品安全评估提供重要资料,并指南监管决策和安全评估。
由于受到工业成长、不断变化的监管环境和产品安全意识不断增强等因素影响的动态市场形势,亚太地区在预测期内占据了最大份额。该地区包括中国、日本、印度和韩国等多元化经济体,透过严格的毒性测试通讯协定来帮助确保产品安全。此外,消费者对个人保健产品和药品的认识不断提高,进一步推动了该地区对全面经皮毒性测试的需求。
由于欧洲对消费者安全的重视以及向试管内和In Silico模型等替代方法的重大转变,预计欧洲在预测期内将经历最高的复合年增长率。 Charles River Laboratories International、MatTek Corporation、Intertek Group 和 GE Healthcare 等主要企业正在为经皮毒性评估的准确性和效率做出贡献。此外,美国环保署 (EPA) 和食品药物管理局(FDA) 等机构制定的严格监管标准强调了全面毒性测试的重要性,从而推动了该地区的发展。
According to Stratistics MRC, the Global Dermal Toxicity Testing Market is accounted for $2.32 billion in 2023 and is expected to reach $4.60 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Dermal toxicity testing is a scientific method employed to assess the potential harmful effects of chemical substances when they come into contact with the skin. This type of testing is crucial for evaluating the safety of various products, including cosmetics, pharmaceuticals, and industrial chemicals. Various parameters are assessed during dermal toxicity testing, such as skin appearance, erythema (redness), edema (swelling), and other signs of irritation.
According to the Cancer Research Institute, the number of active drugs in development grew by more than 90%, to 3,876 in 2019. Long-term rodent carcinogenicity studies for assessing the carcinogenic potential of drugs in humans are currently being examined.
Increasing research and development activities
The growth in R&D activities underscores the pivotal role of the development of new products and formulations to introduce innovative and safe products to the market. Comprehensive dermal toxicity testing becomes imperative to assess the safety profile of these advancements. Further, by the need to align with evolving regulatory standards, safeguard public health, and instill consumer confidence in the safety of newly developed products, the demand for dermal toxicity testing services is propelled.
High cost
Dermal toxicity testing requires specialized facilities and equipment to ensure accurate and reliable results. The costs of maintaining such facilities, acquiring and maintaining testing equipment, and employing skilled personnel can be significant. The complexity and diversity of substances that require testing further contribute to the costs. Furthermore, as regulatory requirements evolve, additional tests or updated methodologies may be necessary, leading to increased costs for compliance, which is hampering this market expansion.
Rising consumer awareness
Rising awareness regarding skin health and safety prompts consumers to scrutinize product labels and demand transparency from manufacturers. Consumers are becoming more conscious of the potential risks associated with exposure to certain chemicals present in personal care products, cosmetics, and pharmaceuticals. Additionally, this emphasis on safety aligns with the broader trend of consumers seeking products that prioritize health and environmental sustainability, which are driving this market size.
Limited standardization
The absence of standardized protocols and guidelines made it challenging to make accurate risk assessments and interpret test results obtained from different laboratories or studies. It also made it difficult to establish consistent criteria for determining the safety of substances in relation to dermal exposure. Moreover, the lack of harmonization resulted in inefficiencies and increased costs for both regulators and industry stakeholders, which are hindering this market expansion.
Covid-19 Impact
The COVID-19 pandemic has had several negative impacts on the dermal toxicity testing market. The dermal toxicity testing market relies heavily on the pharmaceutical, cosmetic, and chemical sectors, all of which experienced disruptions during the pandemic. Laboratory closures, restricted access to facilities, and limitations on workforce mobility impeded the smooth conduct of dermal toxicity tests, affecting timelines for product approvals and introductions. Furthermore, the economic downturn has prompted some businesses to reconsider their investments in non-essential testing services, affecting overall market growth.
The in-silico modeling segment is expected to be the largest during the forecast period
The in-silico modeling segment is estimated to hold the largest share, due to they aim to provide accurate predictions of dermal toxicity by simulating molecular interactions, absorption rates, and potential adverse effects on the skin. These models contribute to the reduction of animal testing, aligning with ethical considerations and regulatory efforts to minimize animal use in testing procedures. In addition, advancements in technology, such as machine learning and artificial intelligence, enhance the accuracy and reliability of in-silico models, making them valuable tools in toxicology assessments which are driving this segment's growth.
The skin corrosion tests segment is expected to have the highest CAGR during the forecast period
The skin corrosion tests segment is anticipated to have highest CAGR during the forecast period. It refers to severe damage to the skin, often characterized by the destruction of skin tissue, leading to chemical burns. These tests typically involve the application of the test substance to the skin of experimental animals or in vitro models, and observations are made to determine the extent of skin damage. Furthermore, the results help classify substances as corrosive or non-corrosive, guiding regulatory decisions and safety assessments by providing essential data for product safety assessments, which is boosting this segment expansion.
Asia Pacific commanded the largest market share during the extrapolated period owing to a dynamic landscape influenced by factors such as industrial growth, regulatory developments, and increasing awareness of product safety. The region encompasses diverse economies, including China, Japan, India, South Korea, and others, contributing to ensuring the safety of products through robust toxicity testing protocols. Moreover, increased awareness among consumers regarding personal care and pharmaceutical products further propels the demand for comprehensive dermal toxicity testing in this region.
Europe is expected to witness highest CAGR over the projection period, owing to a strong focus on consumer safety and cutting-edge testing methodologies, with a notable shift towards alternative methods such as in vitro and in silico models. Key players such as Charles River Laboratories International, MatTek Corporation, Intertek Group, and GE Healthcare contribute to the accuracy and efficiency of dermal toxicity assessments. Further, stringent regulatory standards set by agencies like the U.S. Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) emphasize the importance of comprehensive toxicity testing, thereby driving this region.
Key players in the market
Some of the key players in the Dermal Toxicity Testing Market include SGS S.A, Bio-Rad Laboratories Inc., Charles River Laboratories International, Inc., Catalent, Inc., Eurofins Scientific Inc, Thermo Fisher Scientific, Inc., Covance, Inc , GE Healthcare, Qiagen N.V., Merck KgaA, Intertek Group, MatTek Corporation and Evotec.
In December 2023, GE HealthCare and Nantworks AirStrip announced an agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems.
In December 2023, SGS is pleased to announce the signing of an agreement to divest its crop science operations in 14 countries to Eurofins Scientific.
In November 2023, GE HealthCare (Nasdaq: GEHC) and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.
In October 2023, SGS is pleased to have signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors.